Objective: To assess the effectiveness of testosterone undecanoate
on sperm motility and pregnancy incidence in men with
Design: Retrospective and clinical trial.
Participants: Fifty men with asthenospermia.
Interventions: Patients were randomized to rec
eive placebo, T
undecanoate (80 mg per day).
Main outcome measures: Pregnancy incidence and sperm
characteristics after 1, 2 and 3 months of medication and 3
months after the end of the trial.
Results: Compared with the placebo, T undecanoate treatment
produced a satisfactory improvement of seminal motility
(F=55.904, P=0.000). In the groups treated with T undecanoate,
the incidence of pregnancy was 28.2% while the incidence of
pregnancy of placebo groups was 11.1%. In active treatment
groups, twenty six people took T undecanoate for more than 3
months. In the 3 months, semen volume showed no statistical
difference (F=1.206, P=0.312) before and after treatment,
sperm concentration and motility showed statistical difference.
Motility grade a showed significantly higher increment in 2 and 3
months after treatment than 1 month and there was no statistical
difference between 2 and 3 months. So did grade b.
Conclusions: The results indicate that T undecanoate decreases
sperm concentration and increases seminal motility, leading to a
higher incidence of pregnancy in couples with infertility related